Lebrikizumab maintenance dosing achieves dermatitis clearance up to 2 years
Click Here to Manage Email Alerts
Key takeaways:
- Both 2-week and monthly dosing of lebrikizumab maintained skin clearance and reduced itch among patients with atopic dermatitis.
- Also, 62% of patients experienced mild to moderate adverse events.
Maintenance dosing of lebrikizumab sustained skin clearance, relieved itch and reduced disease severity for up to 2 years in patients with moderate to severe atopic dermatitis, Eli Lilly and Company announced in a press release.
The data compiled from ADjoin, a long-term extension trial stemming from ADvocate 1, ADvocate 2 and ADhere, was presented at the 43rd Annual Fall Clinical Dermatology Conference.
“What our patients want is the ability to potentially take a drug not so often,” Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at Icahn School of Medicine at Mount Sinai, told Healio. “Now, we have another treatment that can be given either every 2 weeks or every 4 weeks.”
Patients who achieved IGA 0/1 or EASI 75 at weeks 16 in ADvocate 1, ADvocate 2 or ADhere were enrolled in ADjoin and received lebrikizumab 250 mg for 2 years, dosed either every 2 weeks or monthly.
Results showed that both monthly and 2-week dosages of lebrikizumab were effective long-term in maintaining clearance and reducing itch among patients with AD.
“The fact that every 4-week dosing can maintain efficacy is a big deal,” Gutman-Yassky explained.
Of 99 patients from ADvocate 1 and 2 that were treated monthly with lebrikizumab, 76% achieved IGA 0/1, 96% achieved EASI 75 and 83% achieved EASI 90, with 90% experiencing a 4-point improvement in itch according to the Pruritus Numerical Rating Scale (NRS).
Of the 82 patients dosed at two-week intervals from the ADvocate trials, 86% achieved IGA 0/1, 96% EASI 75 and 82% EASI 90. Additionally, all patients experienced a 4-point or greater improvement in Pruritus NRS.
Similar results were seen in the patients dosed monthly and every 2 weeks from the ADhere trial, with 79% and 84% reaching IGA 0/1, 96% and 95% attaining EASI 75, and 72% and 85% achieving EASI 90, respectively. Further, 90% and 82% saw a 4-point or greater improvement in Pruritis NRS.
The safety profile of lebrikizumab was consistent with previous studies. Sixty-two percent of patients in ADjoin reported adverse events, most of which were mild to moderate in severity, including conjunctivitis, injection site reactions and shingles. Less than 3% of patients discontinued treatment due to adverse events.
“We are excited to add another treatment to our box that can clear, or almost clear, a high proportion of patients, and potentially maintain that clearance with every 2-week or every 4-week dosing over time,” Guttman-Yassky said.
Collapse
Read more about
Click Here to Manage Email Alerts